Cerebrolysin
Porcine brain-derived peptide preparation
A preparation of low-molecular-weight neuropeptides and free amino acids derived from pig brain, given by intravenous infusion for stroke and cognitive impairment. The trial literature exists but is methodologically contested.
- Category
- Cognitive
- Half-life
- Not applicable to a multi-peptide preparation; activity is measured by clinical effect rather than plasma kinetics
- Cycle length
- Clinical courses of 10 to 20 days, sometimes repeated
- Level
- intermediate
Overview
Cerebrolysin is not a single peptide. It is a standardised mixture of peptides and free amino acids obtained from porcine brain tissue, delivered by intravenous infusion rather than injection or oral dosing. It has been used clinically for decades in parts of Europe and Asia, especially in acute ischaemic stroke and vascular dementia, while remaining unapproved in the United States. It belongs in this library because it appears repeatedly in discussions of cognitive enhancement, and because it illustrates a category problem: a preparation whose active components are not individually characterised is very difficult to study to modern standards, which is exactly what its evidence review shows.
How it works
The preparation is designed to mimic endogenous neurotrophic support, and its components are reported to act on neurotrophic signalling, neuronal survival and synaptic plasticity in models of ischaemic and degenerative injury. Because it is a mixture rather than a defined molecule, no single mechanism has been established; the pharmacology is a composite of many small peptide fragments, and their individual contributions are unknown.
Reported benefits
- Some trials report improved functional outcomes after acute ischaemic stroke
- Reported improvements on cognitive scales in vascular dementia studies
- Neurotrophic and neuroprotective effects in animal models of brain injury
- Widely used clinically in some countries for decades
Reported benefits describe what the published literature and user reports suggest — not a promise of outcome for any individual.
Dosing reference
Clinical use has typically involved 10 to 30 mL of the infusion solution per day, given intravenously in courses of 10 to 20 days under medical supervision. There is no approved product or approved dose in the United States.
This is an intravenous clinical preparation, not a reconstituted research powder, and the courses described in trials were delivered in hospital settings. Self-administration of a brain-derived biologic carries infection and immune-reaction risks that the clinical setting is designed to manage.
Clinical and community reporting: 5–30 mL daily by intramuscular or intravenous route for ten to twenty days, repeated in courses, with medical supervision. This is not a self-administered protocol and should not be treated as one.
These figures are what people report using in public communities. They have not been studied, verified or checked against certificates of analysis, and they are not a recommendation, a prescription or a target to aim for.
Where the reported amounts come from
Amounts are reproduced for education only. Doses from trials cannot be assumed to suit anyone else, and community-reported amounts are frequently wrong. Self-administering unapproved compounds carries serious risk.
The research picture
Cerebrolysin has a substantial but contested literature: dozens of trials, several systematic reviews and meta-analyses, and a Cochrane review of its use in acute ischaemic stroke that concluded the evidence was limited by trial quality and heterogeneity. Some individual studies reported better functional outcomes and cognitive scores; the reviews have consistently stopped short of calling the evidence conclusive. There is also a fundamental challenge with studying it: because the preparation is a mixture of many fragments, its active constituents, dose–response behaviour and mechanism cannot be pinned down the way a single peptide's can. Patients considering it should understand that they are being asked to accept a composite agent on the basis of trials that reviewers keep describing as encouraging but insufficient.
Preclinical & non-clinical data
A porcine brain-derived peptide preparation used clinically in several countries for stroke and dementia. Animal studies show neurotrophic signalling; the controlled human literature is mixed, with positive European trials and later systematic reviews rating the evidence quality low to moderate.
Non-clinical data comes from cells and animals unless stated otherwise. It answers whether a compound is worth studying in people — not whether it is safe or effective in them.
What users report
Most reporting comes from people with diagnosed neurological conditions, post-concussion symptoms or long-running brain fog, describing clinic-administered intravenous courses of ten to twenty days with improved cognition, mood and stamina, then a fade over weeks. The consistent caveat in these accounts is that the benefit only held for as long as the courses continued, and that effects were hard to separate from the attention and care that came with the treatment itself.
Where these reports come from
These are unverified personal accounts collected from public sources. They are not evidence of effectiveness or safety, they have not been independently checked, and they are not a recommendation to use anything described.
Possible side effects
- Dizziness and headache during infusion
- Agitation or confusion in some patients
- Injection-site and infusion reactions
- Hypersensitivity reactions to the biologic preparation
Safety notes
As a porcine-derived biologic given intravenously, it carries infection and immune-reaction risks that require clinical oversight. It is not approved in the United States, and its use in dementia is not supported by evidence strong enough for a standard guideline recommendation. Anyone with a history of hypersensitivity to brain-derived preparations, or who is pregnant, should avoid it.
Stacking
Not a compound for stacking. It is given as a defined intravenous course in clinical settings, and combining it with other unapproved cognitive compounds removes any ability to interpret a change in symptoms.
Related compounds
Semax
ACTH(4-10) analogue
Cognitive
A Russian nootropic peptide with genuine human data behind it.
DSIP
Delta sleep-inducing peptide — nine amino acids
Cognitive
A sleep peptide from the 1970s whose human evidence never matched its name.
Dihexa
N-hexanoic-Tyr-Ile-(6) aminohexanoic amide — angiotensin IV analogue
Cognitive
A cognitive-enhancement candidate with striking animal data and no human testing.